drugset / Trial / NCT04819464
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod
RandomizedSequentialOpen-labelOther
Summary
This is a prospective, open-label, single-dose, phase 1 study, to assess the effect of mild and moderate hepatic impairment on the pharmacokinetics of cenerimod (ACT-334441).
Timeline
- Start
- 2021-08-25
- Primary completion
- 2024-08-18
- Completion
- 2024-08-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cenerimod | Small molecule | 0.5 mg | Oral |
Indications
No indication recorded.